[1]荣　蓉a,古　颖a,高　翔a,等.前列腺癌组织肝激酶B1，Rab鸟嘌呤核苷酸交换因子-5mRNA表达水平与临床病理特征和预后的相关性研究[J].现代检验医学杂志,2021,36(06):1-5.[doi:10.3969/j.issn.1671-7414.2021.06.001]
　RONG Rong,GU Ying,GAO Xiang,et al.Correlation between the Expression Levels of Liver Kinase B1, Rab Guanine Nucleotide Exchange Factor-5 mRNA in Prostate Cancer Tissues and Its Clinicopathological Characteristics and Prognosis[J].Journal of Modern Laboratory Medicine,2021,36(06):1-5.[doi:10.3969/j.issn.1671-7414.2021.06.001]
点击复制

前列腺癌组织肝激酶B1，Rab鸟嘌呤核苷酸交换因子-5mRNA表达水平与临床病理特征和预后的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第36卷
期数:
2021年06期
页码:
1-5
栏目:
论　著
出版日期:
2021-12-15

文章信息/Info

Title:
Correlation between the Expression Levels of Liver Kinase B1, Rab Guanine Nucleotide Exchange Factor-5 mRNA in Prostate Cancer Tissues and Its Clinicopathological Characteristics and Prognosis
文章编号:
1671-7414（2021）06-001-06
作者:
荣　蓉a; 古　颖a; 高　翔a; 张　磊b
（首都医科大学附属北京中医医院a.检验科;b.泌尿外科 ,北京 100010)
Author(s):
RONG Rong;  GU Ying;  GAO Xiang;  et al
（a. Department of Clinical Laboratory;b. Department of Urology Surgery, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing 100010,China）
关键词:
前列腺癌; 肝激酶B1; Rab鸟嘌呤核苷酸交换因子-5; 临床病理特征
分类号:
R737.25;R730.43
DOI:
10.3969/j.issn.1671-7414.2021.06.001
文献标志码:
A
摘要:
目的　研究前列腺癌患者癌组织中肝激酶B1（liver kinase B1，LKB1）及Rab鸟嘌呤核苷酸交换因子-5 (Rab guanine nucleotide exchage factor-5，Rab EX-5) mRNA表达及临床意义。方法　应用实时荧光定量PCR（qRT-PCR）检测92例前列腺癌组织和80例良性前列腺增生组织中LKB1及RabEX-5 mRNA的表达，比较LKB1，RabEX-5 mRNA表达组间差异及与临床病理特征的关系。Pearson线性相关分析LKB1与RabEX-5 mRNA表达的相关性。Kaplan-Meier生存分析LKB1，RabEX-5 mRNA表达与前列腺癌患者生存预后的关系。多因素COX回归分析影响前列腺癌患者生存预后的危险因素。结果　与前列腺增生组织相比，前列腺癌组织中RabEX-5 mRNA表达明显升高（1.311±0.374 vs 0.457±0.083），差异有统计学意义（t=20.758，P=0.000），而LKB1 mRNA表达显著降低（0.373±0.052 vs 1.234±0.268），差异有统计学意义（t=30.181，P=0.000）。LKB1，RabEX-5 mRNA表达与Gleason评分、骨转移、TNM分期有关（t=2.419~9.965，均P<0.05），与年龄、前列腺特异抗原（PSA）水平无关（t=0.379~1.453，均P>0.05）。前列腺癌组织中LKB1与RabEX-5 mRNA的表达呈显著负相关（r=-0.402，P=0.000）。低LKB1表达组3年总体生存率低于高LKB1表达组（χ2=55.605，P=0.000），高RabEX-5表达组3年总体生存率低于低RabEX-5表达组（χ2=29.435，P=0.000）。多因素COX回归分析结果表明，Gleason评分≥7分（OR=2.671，P=0.018）、骨转移（OR=1.528，P=0.031）、TNM分期为Ⅲ期（OR=1.634，P=0.037），LKB1 mRNA低表达（OR=1.764，P=0.008）及RabEX-5 mRNA高表达（OR=2.587，P=0.000）是影响前列腺癌患者生存预后的危险因素（P<0.05）。结论　前列腺癌组织中RabEX-5 mRNA表达升高，而LKB1 mRNA表达降低，二者共同参与前列腺癌的发生发展，有望成为评估前列腺癌患者预后的组织肿瘤标志物。
Abstract:
Objective　To study the expression and clinical significance of liver kinase B1 (LKB1) and Rab guanine nucleotide exchange factor-5 (RabEX-5) mRNA in cancer tissues of prostate cancer patients. Methods　Quantitative real-time PCR (qRT-PCR) was used to detect the expression of LKB1 and RabEX-5 mRNA in 92 cases of prostate cancer tissues and 80 cases of benign prostatic hyperplasia tissues. LKB1 and RabEX-5 mRNA expression differences between groups and their relationship with clinicopathological characteristics were compared. Pearson linear correlation analysis was used to analyze the correlation between LKB1 and RabEX-5 mRNA expression. Kaplan-Meier survival analysis were used to analyze the relationship between LKB1 and RabEX-5 expression and the survival prognosis of prostate cancer patients. Multivariate COX regression analysis was used to analyze the risk factors affecting the survival and prognosis of prostate cancer patients. Results　Compared with prostatic hyperplasia tissues, the expression of RabEX-5 mRNA in prostate cancer tissue was significantly increased(1.311±0.374 vs 1.457±0.083), the difference was statisticall significant(t=20.758, P=0.000), while the expression of LKB1 mRNA was significantly decreased (0.373±0.052 vs 1.234±0.268), the difference was statistically significant(t=30.181, P=0.000). The expression of LKB1 and RabEX-5 mRNA were related to Gleason score, bone metastasis and TNM stage (t=2.419~9.965, all P<0.05), but not with age or prostate specific antigen (PSA) level (t=0.379~1.453, all P>0.05). The expression of LKB1 and RabEX-5 mRNA in prostate cancer tissue was significantly negatively correlated (r=-0.402 P=0.000). The 3-year overall survival rate of the low LKB1 expression group was lower than that of the high LKB1 expression group（χ2=55.605, P=0.000）, and the 3-year overall survival rate of the high RabEX-5 expression group was lower than that of the low RabEX-5 expression group（χ2=29.435, P=0.000）. Multivariate Cox regression analysis showed that Gleason score ≥7 scores（OR=2.671，P=0.018）, bone metastasis（OR=1.528，P=0.031）, TNM stage Ⅲ（OR=1.634，P=0.037）, low expression of LKB1 mRNA（OR=1.764，P=0.008） and high expression of RabEX-5mRNA（OR=2.587，P=0.000）were risk factors affecting the survival prognosis of prostate cancer patients (P<0.05). Conclusion　RabEX-5 mRNA expression was increased in prostate cancer tissues, while LKB1 mRNA expression is decreased. The two were jointly involved in the occurrence and development of prostate cancer. They are expected to become tissue tumor markers that indicate the prognosis of prostate cancer patients.

参考文献/References:

[1] PERNAR C H, EBOT E M, WILSON K M, et al. Theepidemiology of prostate cancer[J]. Cold Spring HarborPerspectives in Medicine, 2018, 8(12): a030361.
[2] 李星，曾晓勇．中国前列腺癌流行病学研究进展[J].肿瘤防治研究, 2021, 48(1):98-102.LI Xing, ZENG Xiaoyong. Advances in epidemiologyof prostate cancer in China [J]. Cancer Research onPrevention and Treatment, 2021, 48(1):98-102.
[3] 潘良明, 沈菲菲, 马晓英, 等. 血清前列腺健康指数对tPSA 灰区前列腺癌患者的诊断价值探讨[J]．现代检验医学杂志, 2021, 36(1):72-76, 99.PAN Liangming, SHEN Feifei, MA Xiaoying, et al.Diagnostic value of serum prostate health index inprostate cancer patients with PSA gray area [J]. Journalof Modern Laboratory Medicine, 2021, 36(1):72-76, 99.
[4] YANG Cong, DING Hongyu, YANG Yang, et al. BAP1regulates AMPK-mTOR signalling pathway throughdeubiquitinating and stabilizing tumour-suppressorLKB1[J]. Biochemical and Biophysical ResearchCommunications, 2020, 529(4): 1025-1032.
[5] KITAJIMA S, IVANOVA E, GUO S, et al. Suppressionof Sting associated with LKB1 loss in KRAS-Drivenlung cancer[J]. Cancer Discovery, 2019, 9(1): 34-45.
[6] BUENSUCESO A, RAMOS-VALDES Y, DIMATTIA GE, et al. AMPK-independent LKB1 activity is required forefficient epithelial ovarian cancer metastasis[J]. MolecularCancer Research: 2020, 18(3): 488-500.
[7] ZHANG J S, YANG L Q, DU B R, et al. HigherRABEX-5 mRNA predicts unfavourable survival inpatients with colorectal cancer[J]. European Review forMedical and Pharmacological Sciences, 2017, 21(10):2372-2376.
[8] KANG Lili, HAO Xuwen, TANG Yanping, et al.RABEX-5 overexpression in gastric cancer is correlatedwith elevated MMP-9 level[J]. American Journal ofTranslational Research, 2016, 8(5): 2365-2374.
[9] 闫瑾, 李小珍, 杨飞. 外周血前列腺癌抗原3 基因检测对前列腺癌诊断的meta 分析[J]. 现代检验医学杂志, 2019, 34(5):40-44, 51.YAN Jin, LI Xiaozhen, YANG Fei. Validity of PCA3gene test in peripheral blood for prostate cancerdiagnosis:A meta-analysis [J]. Journal of ModernLaboratory Medicine, 2019, 34(5):40-44, 51.
[10] 李星, 王桎仙, 曾晓勇. 原发灶减瘤手术在转移性前列腺癌的研究进展[J]. 现代泌尿生殖肿瘤杂志,2020, 12(3):185-188.LI Xing, WANG Zhixian, ZENG Xiaoyong. Researchprogress of primary cytoreductive surgery in metastaticprostate cancer[J]. Journal of Modern UrogenitalOncology, 2020, 12(3):185-188.
[11] CICCARESE F, ZULATO E, INDRACCOLO S.LKB1/AMPK pathway and drug response in cancer:a therapeutic perspective[J]. Oxidative Medicine andCellular Longevity, 2019(19): 8730816.
[12] SOUROULLAS G P, FEDORIW Y, STAUDT L M, etal. LKB1 deletion in murine B lymphocytes promotescell death and cancer[J]. Experimental Hematology,2017, 51(4): 63-70.e1.
[13] SKOULIDIS F, HEYMACH J V. Co-occurring genomicalterations in non-small-cell lung cancer biology andtherapy[J]. Nature Reviews Cancer, 2019, 19(9): 495-509.
[14] SKOULIDIS F, GOLDBERG M E, GREENAWALT DM, et al. STK11/LKB1 mutations and PD-1 inhibitorresistance in KRAS-Mutant lung adenocarcinoma[J].Cancer Discovery, 2018, 8(7): 822-835.
[15] ZHANG Ming, LI Hai, ZHANG Yun, et al. OncogenicmiR-744 promotes prostate cancer growth throughdirect targeting of LKB1[J]. Oncology Letters, 2019,17(2): 2257-2265.
[16] GALAN-COBO A, SITTHIDEATPHAIBOON P,QU Xiao, et al. LKB1 and KEAP1/NRF2 pathwayscooperatively promote metabolic reprogramming withenhanced glutamine dependence in KRAS-Mutant lungadenocarcinoma[J]. Cancer Research, 2019, 79(13):3251-3267.
[17] CHEN Song, FANG Lijun, GUO Wei, et al. Controlof T(reg) cell homeostasis and immune equilibrium byLKB1 in dendritic cells[J]. Nature Communications,2018, 9(1): 775-787.
[18] DOHLMAN H G, CAMPBELL S L. Regulation oflarge and small G proteins by ubiquitination[J]. TheJournal of Biological Chemistry, 2019, 294(49): 18613-18623.
[19] 杨富兰．RabEX-5 在肝细胞癌组织中的表达及在预后中的临床意义[J]. 中国现代普通外科进展,2020,23(7):505-509, 566.YANG Fulan. Rabex-5 expression in hepatocellularcarcinoma and its clinical significance in prognosis[J]. Chinese Journal of Current Advances in GeneralSurgery, 2020, 23(7):505-509, 566.
[20] YANG Haitang. Co-Occurring LKB1 deficiencydeterminates the susceptibility to ERK-Targeted therapyin Ras-Mutant lung cancer[J]. Journal of ThoracicOncology, 2020, 15(4): e58-e59.
[21] XU Lizhong, LUBKOV V, TAYLOR L J, et al.Feedback regulation of Ras signaling by RabEX-5-mediated ubiquitination[J]. Current Biology , 2010,20(15): 1372-1377.

相似文献/References:

[1]廖洪利,米叶赛尔·阿不都拉.粘着斑激酶在前列腺癌中表达的研究[J].现代检验医学杂志,2016,31(05):132.[doi:10.3969/j.issn.1671-7414.2016.05.038]
　LIAO Hong-li,MIYESAIER·Abdula.Research on Expression of FAK in Prostate Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(06):132.[doi:10.3969/j.issn.1671-7414.2016.05.038]
[2]范维肖,刁艳君,马越云,等.超速离心法与QIAGEN膜亲和柱法提取前列腺癌细胞培养上清外泌体的方法学比较[J].现代检验医学杂志,2019,34(03):6.[doi:10.3969/j.issn.1671-7414.2019.03.002]
　FAN Wei-xiao,DIAO Yan-jun,MA Yue-yun,et al.Comparison of Ultracentrifugation and Membrane Based-Affinity ColumnMethods in Exosome Isolation from Supernatants of Prostate Cancer Cells[J].Journal of Modern Laboratory Medicine,2019,34(06):6.[doi:10.3969/j.issn.1671-7414.2019.03.002]
[3]潘良明,沈菲菲,马晓英,等.血清前列腺健康指数对 tPSA灰区前列腺癌患者的诊断价值探讨[J].现代检验医学杂志,2021,36(01):72.[doi:10.3969/j.issn.1671-7414.2021.01.019]
　PAN Liang-ming,SHEN Fei-fei,MA Xiao-ying,et al.Diagnostic Value of Serum Prostate Health Index in Prostate Cancer Patients with PSA Gray Area[J].Journal of Modern Laboratory Medicine,2021,36(06):72.[doi:10.3969/j.issn.1671-7414.2021.01.019]
[4]何　跃,梁　晶,文礼红,等.前列腺癌患者血清IL-17和IL-35水平表达与临床病理特征以及预后的关系研究[J].现代检验医学杂志,2021,36(04):96.[doi:10.3969/j.issn.1671-7414.2021.04.020]
　HE Yue,LIANG Jing,WEN Li-hong,et al.Study on the Relationship between Serum IL-17, IL-35 Levels andClinicopathological Features and Prognosis in Patients with Prostate Cancer[J].Journal of Modern Laboratory Medicine,2021,36(06):96.[doi:10.3969/j.issn.1671-7414.2021.04.020]
[5]张士保,朱斐煜,谢瑞玉,等.CircRNA-100395 基因通过启动子区甲基化调控miRNA-136-5p/Smad3 轴促进前列腺癌细胞增殖及侵袭的机制研究[J].现代检验医学杂志,2022,37(05):44.[doi:10.3969/j.issn.1671-7414.2022.05.010]
　ZHANG Shi-bao,ZHU Fei-yu,XIE Rui-yu,et al.Mechanism of CircRNA-100395 Promoter Methylation Promoting Prostate Cancer Cells Proliferation and Invasion by Regulating miRNA-136-5p/Smad3 Axis[J].Journal of Modern Laboratory Medicine,2022,37(06):44.[doi:10.3969/j.issn.1671-7414.2022.05.010]
[6]阴铭迪,李 林.前列腺癌实验室诊断的最新进展[J].现代检验医学杂志,2022,37(05):194.[doi:10.3969/j.issn.1671-7414.2022.05.039]
　YIN Ming-di,LI Lin.Recent Advances in Laboratory Diagnosis of Prostate Cancer[J].Journal of Modern Laboratory Medicine,2022,37(06):194.[doi:10.3969/j.issn.1671-7414.2022.05.039]
[7]郑江婷,寸淑娥,尹 冶,等.长链非编码RNA 在前列腺癌治疗抵抗中作用机制的研究进展[J].现代检验医学杂志,2023,38(01):199.[doi:10.3969/j.issn.1671-7414.2023.01.038]
　ZHENG Jiang-ting,CUN Shu-e,YIN Ye,et al.Research Progress of Long Non-coding RNA in the Therapeutic Resistance of Prostate Cancer[J].Journal of Modern Laboratory Medicine,2023,38(06):199.[doi:10.3969/j.issn.1671-7414.2023.01.038]
[8]孙 飞,黎春明.基于免疫细胞组织浸润的免疫评分模型预测前列腺癌免疫治疗效果及预后分析研究[J].现代检验医学杂志,2023,38(03):189.[doi:10.3969/j.issn.1671-7414.2023.03.035]
　SUN Fei,LI Chun-ming.Prediction of Immunotherapy Effect and Prognosis of Prostate Cancer Based on Immune Cell Tissue Infiltration Immune Score Model[J].Journal of Modern Laboratory Medicine,2023,38(06):189.[doi:10.3969/j.issn.1671-7414.2023.03.035]

备注/Memo

备注/Memo:
基金项目：2017年北京市科技发展指导性计划项目（BJSW2017018）。作者简介：荣蓉（1979-），女，本科，主管检验师，研究方向：医学临床检验，E-mail：beijingzy2021@163.com。通讯作者：高翔（1975-），女，本科，副主任技师，研究方向：医学临床检验。
更新日期/Last Update: 1900-01-01